Pain treatment in cancer patients - an update

被引:0
作者
Hennig, C. [1 ]
Koch, T. [1 ]
Sabatowski, R. [1 ]
机构
[1] Univ Klinikum Carl Gustav Carus Dresden, Klin & Poliklin Andsthesiol & Intensivtherapie, D-01307 Dresden, Germany
来源
ANASTHESIOLOGIE & INTENSIVMEDIZIN | 2011年 / 52卷
关键词
Cancer Pain; Treatment; Breakthrough Pain; Opioids; Palliative Care; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BREAKTHROUGH PAIN; MORPHINE; ACETAMINOPHEN; COMBINATION; PARACETAMOL; PREVALENCE; ANALGESIA; OPIOIDS; NSAIDS;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Pain is one of the most common symptoms in cancer patients. Its intensity and character correlate with the aetiology, site and stage of the cancer, as well as the extent of metastases. Pathophysiologically, nociceptive, neuropathic and mixed (nociceptive and neuropathic) pain syndromes can be differentiated. In addition to chronic pain, some patients also suffer from cancer-related breakthrough pain. To ensure adequate pain control in such patients, a detailed medical history and a meticulous physical examination, together with a broad knowledge of the pain syndromes presenting, and also multidisciplinary pain management strategies, are essential. In addition to analgesics administered in accordance with a rigid time schedule, proper dosing, individual dose titration and the prescription of co-analgesics are important. In addition to the basic therapy, adequate medication must also be available to the patient for the treatment of possible breakthrough pain. Furthermore, since the quality of life of cancer pain patients may be compromised by other cancer- and/or treatment-related symptoms such as constipation, fatigue, vomiting, etc. a comprehensive therapeutic approach is needed.
引用
收藏
页码:415 / 430
页数:16
相关论文
共 48 条
[41]   Rectal and parenteral paracetamol, and paracetamol in combination with NSAIDs, for postoperative analgesia [J].
Romsing, J ;
Moiniche, S ;
Dahl, JB .
BRITISH JOURNAL OF ANAESTHESIA, 2002, 88 (02) :215-226
[42]  
Singleton PA, 2010, FUTURE ONCOL, V6, P1237, DOI [10.2217/fon.10.99, 10.2217/FON.10.99]
[43]   Impact of CYP2D6 genotype on postoperative tramadol analgesia [J].
Stamer, UM ;
Lehnen, K ;
Höthker, F ;
Bayerer, B ;
Wolf, S ;
Hoeft, A ;
Stuber, F .
PAIN, 2003, 105 (1-2) :231-238
[44]   Breakthrough pain in malignant and non-malignant diseases:: a review of prevalence, characteristics and mechanisms [J].
Svendsen, KB ;
Andersen, S ;
Arnason, S ;
Arnér, S ;
Breivik, H ;
Heiskanen, T ;
Kalso, E ;
Kongsgaard, UE ;
Sjogren, P ;
Strang, P ;
Bach, FW ;
Jensen, TS .
EUROPEAN JOURNAL OF PAIN, 2005, 9 (02) :195-206
[45]   Methylnaltrexone for opioid-induced constipation in advanced illness [J].
Thomas, Jay ;
Karver, Sloan ;
Cooney, Gail Austin ;
Chamberlain, Bruce H. ;
Watt, Charles Kevin ;
Slatkin, Neal E. ;
Stambler, Nancy ;
Kremer, Alton B. ;
Israel, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (22) :2332-2343
[46]  
Twycross R., 2002, Palliative care formulary 1998
[47]   Paracetamol for perioperative analgesia [J].
Zahn, P. K. ;
Sabatowski, R. ;
Schug, S. A. ;
Stamer, U. M. ;
Pogatzki-Zahn, E. M. .
ANAESTHESIST, 2010, 59 (10) :940-952
[48]  
Zeppetella G, 2003, EXPERT OPIN PHARMACO, V4, P493, DOI 10.1517/eoph.4.4.493.22220